Kuros Biosciences Valuation
Is KURN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KURN?
Other financial metrics that can be useful for relative valuation.
|What is KURN's n/a Ratio?|
Price to Sales Ratio vs Peers
How does KURN's PS Ratio compare to its peers?
|Company||PS||Estimated Growth||Market Cap|
RLF Relief Therapeutics Holding
MOLN Molecular Partners
KURN Kuros Biosciences
Price-To-Sales vs Peers: KURN is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (12.2x).
Price to Earnings Ratio vs Industry
How does KURN's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Sales vs Industry: KURN is good value based on its Price-To-Sales Ratio (2.7x) compared to the European Biotechs industry average (9.3x)
Price to Sales Ratio vs Fair Ratio
What is KURN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.7x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate KURN's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of KURN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate KURN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate KURN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.